These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 19179306)

  • 41. NGR-modified pH-sensitive liposomes for controlled release and tumor target delivery of docetaxel.
    Gu Z; Chang M; Fan Y; Shi Y; Lin G
    Colloids Surf B Biointerfaces; 2017 Dec; 160():395-405. PubMed ID: 28965079
    [TBL] [Abstract][Full Text] [Related]  

  • 42. NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells.
    Wang X; Wang Y; Chen X; Wang J; Zhang X; Zhang Q
    J Control Release; 2009 Oct; 139(1):56-62. PubMed ID: 19470394
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of (188)Re-labeled NGR-VEGI protein for radioimaging and radiotherapy in mice bearing human fibrosarcoma HT-1080 xenografts.
    Ma W; Shao Y; Yang W; Li G; Zhang Y; Zhang M; Zuo C; Chen K; Wang J
    Tumour Biol; 2016 Jul; 37(7):9121-9. PubMed ID: 26768609
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel.
    Luo LM; Huang Y; Zhao BX; Zhao X; Duan Y; Du R; Yu KF; Song P; Zhao Y; Zhang X; Zhang Q
    Biomaterials; 2013 Jan; 34(4):1102-14. PubMed ID: 23127332
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting Tissue Factor to Tumor Vasculature to Induce Tumor Infarction.
    Berdel AF; Schwöppe C; Brand C; Harrach S; Brömmel K; Hintelmann H; Lenz G; Liersch R; Heinzow H; Schliemann C; Mesters RM; Berdel WE; Kessler T
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34200318
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An antimicrobial peptide containing NGR motif has potent antitumor activity against CD13+ and CD13- tumor cells.
    Zhang Z; Hou L; Feng L; Huang S; Luo M; Shao S; Zhang X; Gu S; Zhao X
    Tumour Biol; 2015 Sep; 36(10):8167-75. PubMed ID: 25990455
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multiparametric Magnetic Resonance Imaging for Immediate Target Hit Assessment of CD13-Targeted Tissue Factor tTF-NGR in Advanced Malignant Disease.
    Gerwing M; Krähling T; Schliemann C; Harrach S; Schwöppe C; Berdel AF; Klein S; Hartmann W; Wardelmann E; Heindel WL; Lenz G; Berdel WE; Wildgruber M
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34884988
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Arginine-glycine-aspartic polypeptide mediated truncated tissue factor therapy for colorectal carcinoma].
    Huang ZJ; Luo Q; Yan JH; Wang SY
    Zhonghua Wai Ke Za Zhi; 2010 Apr; 48(8):619-24. PubMed ID: 20646482
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature.
    Cao L; Du P; Jiang SH; Jin GH; Huang QL; Hua ZC
    Mol Cancer Ther; 2008 Apr; 7(4):851-61. PubMed ID: 18413798
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
    Sheng W; Shang Y; Li L; Zhen Y
    Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prediction of antiangiogenic treatment efficacy by iron oxide enhanced parametric magnetic resonance imaging.
    Persigehl T; Matuszewski L; Kessler T; Wall A; Meier N; Ebert W; Berdel WE; Heindel W; Mesters R; Bremer C
    Invest Radiol; 2007 Dec; 42(12):791-6. PubMed ID: 18007150
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High-yield expression, purification and characterization of tumor-targeted IFN-alpha2a.
    Meng J; Yan Z; Wu J; Li L; Xue X; Li M; Li W; Hao Q; Wan Y; Qin X; Zhang C; You Y; Han W; Zhang Y
    Cytotherapy; 2007; 9(1):60-8. PubMed ID: 17354103
    [TBL] [Abstract][Full Text] [Related]  

  • 53. APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes.
    Dunne M; Zheng J; Rosenblat J; Jaffray DA; Allen C
    J Control Release; 2011 Sep; 154(3):298-305. PubMed ID: 21640146
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles.
    Li L; Wartchow CA; Danthi SN; Shen Z; Dechene N; Pease J; Choi HS; Doede T; Chu P; Ning S; Lee DY; Bednarski MD; Knox SJ
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1215-27. PubMed ID: 15001266
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
    Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
    Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
    [TBL] [Abstract][Full Text] [Related]  

  • 56. RGD delivery of truncated coagulase to tumor vasculature affords local thrombotic activity to induce infarction of tumors in mice.
    Jahanban-Esfahlan R; Seidi K; Monhemi H; Adli ADF; Minofar B; Zare P; Farajzadeh D; Farajnia S; Behzadi R; Abbasi MM; Zarghami N; Javaheri T
    Sci Rep; 2017 Aug; 7(1):8126. PubMed ID: 28811469
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis and evaluation of novel Tc-99m labeled NGR-containing hexapeptides as tumor imaging agents.
    Kim DW; Kim WH; Kim MH; Kim CG
    J Labelled Comp Radiopharm; 2015 Feb; 58(2):30-5. PubMed ID: 25583160
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice.
    Nilsson F; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2001 Jan; 61(2):711-6. PubMed ID: 11212273
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma.
    Kessler T; Baumeier A; Brand C; Grau M; Angenendt L; Harrach S; Stalmann U; Schmidt LH; Gosheger G; Hardes J; Andreou D; Dreischalück J; Lenz G; Wardelmann E; Mesters RM; Schwöppe C; Berdel WE; Hartmann W; Schliemann C
    Transl Oncol; 2018 Dec; 11(6):1271-1282. PubMed ID: 30125801
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cell-penetrating peptide-doxorubicin conjugate loaded NGR-modified nanobubbles for ultrasound triggered drug delivery.
    Lin W; Xie X; Deng J; Liu H; Chen Y; Fu X; Liu H; Yang Y
    J Drug Target; 2016; 24(2):134-46. PubMed ID: 26176270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.